Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Results filtered:Study status: Closed for Enrollment
The purpose of this study is to test the tolerability, safety, and effectiveness of 12 weeks once-daily fenofibrate in reducing Ischemic Cholangiopathy (IC) incidence after Donation after Circulatory Death (DCD) liver transplantation. Additionally to assess the association between serum markers of cholestasis and development of IC. Tolerability and safety will be assessed as proportions of: drug discontinuation, and new grade 3 or 4 adverse events. Effectiveness will be assessed as incidence of cholangiographically-diagnosed IC and incidence of any IC-related complication.
The purpose of this study is to validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.